CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Insight Molecular Diagnostics Inc. (IMDX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Insight Molecular Diagnostics Inc. (IMDX)

In Vitro & In Vivo Diagnostic Substances · market cap $124M · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
8
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Insight Molecular Diagnostics Inc. (IMDX) is a ~$164M market-cap diagnostic and specialty pharmaceutical company with a diverse pipeline anchored by 99mTc-MIP-1404, a PSMA-targeted imaging agent in Phase 3 for prostate cancer. The company posted a positive data readout on June 16, 2026, and carries approximately $28.2M in cash, representing roughly 11 months of runway at current burn rates. Revenue remains minimal (~$4M in 2025) against persistent net losses exceeding $50M annually.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
99mTc-MIP-1404 InjectionPhase 3Prostate Cancer
99mTc-MIP-1404Phase 2Prostate Cancer
UltratraceTM Iobenguane I 131 ImagingPhase 2Neuroblastoma
NeuVax vaccinePhase 2Breast Cancer
Iodofiltic acid I 123Phase 2Acute Coronary Syndrome
Ultratrace Iobenguane (MIBG) I 131Phase 2Pheochromocytoma
Klarity CL, Cylcosporine/Loteprednol Etabonate Preservative FreePhase 3Dry Eye
UltratraceTM Iobenguane I 131 TherapyPhase 2Neuroblastoma
Price & technical context
3-month
-61.8%
6-month
-71.8%
12-month
-73.8%
52-wk range
$1.59–$7.50
vs 50-day MA
-46.4%
vs 200-day MA
-62.5%
Realized vol
108.0%
Max drawdown
-81.3%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for IMDX (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.